{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:56:26Z","timestamp":1787622986643,"version":"build-2736575974"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100007113","name":"Arak University of Medical Sciences","doi-asserted-by":"publisher","award":["3453"],"award-info":[{"award-number":["3453"]}],"id":[{"id":"10.13039\/501100007113","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Accurate differentiation of prostate cancer (PCa) from benign prostatic hyperplasia (BPH) is challenging due to prostate-specific antigen\u2019s (PSA\u2019s) limited specificity. Circulating and salivary microRNAs (miRNAs) have emerged as promising noninvasive biomarkers. This study aimed to evaluate the diagnostic potential of selected miRNAs in serum and saliva, individually and combined with PSA, for distinguishing PCa from BPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this case-control study, 100 male participants (50 with PCa, 50 with BPH) provided paired serum and saliva samples. Ten candidate miRNAs (miR-182, miR-96, miR-18a, miR-193a-5p, miR-744, miR-573, miR-210, miR-323, miR-101, miR-203) were quantified by real-time quantitative polymerase chain reaction, and PSA levels were measured by enzyme-linked immunosorbent assay. Diagnostic accuracy was assessed via receiver operating characteristic analysis, and correlations between serum and salivary markers were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the BPH group, 8 miRNAs (miR-182, miR-96, miR-18a, miR-193a-5p, miR-744, miR-573, miR-210, miR-323) were significantly upregulated in PCa, whereas miR-101 and miR-203 were downregulated. Salivary miRNA levels strongly mirrored serum profiles (r\u2009=\u20090.70-0.91, P\u2009&amp;lt;\u2009.001). The ROC analysis identified miR-182 and miR-96 as the most discriminatory markers (area under the curve [AUC]\u2009&amp;gt;\u20090.82). Combining PSA with these miRNAs improved diagnostic accuracy (serum PSA\u2009+\u2009miR-182\/96: AUC 0.92\/0.90, 91%\/89% sensitivity, 88.6%\/86.2% specificity; saliva: AUC 0.88\/0.86, 88%\/86% sensitivity, 84%\/82% specificity).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Selected miRNAs, particularly miR-182 and miR-96, reliably differentiate PCa from BPH in both serum and saliva. Integration with PSA further enhances diagnostic performance, and salivary profiling represents a practical, noninvasive approach for early molecular screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag028","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:59:15Z","timestamp":1778716755000},"source":"Crossref","is-referenced-by-count":1,"title":["Salivary and serum microRNAs as noninvasive biomarkers for distinguishing prostate cancer from benign prostatic hyperplasia"],"prefix":"10.1093","volume":"165","author":[{"given":"Mehdi","family":"Salehi","sequence":"first","affiliation":[{"name":"Traditional and Complementary Medicine Research Center, Arak University of Medical Sciences , Arak,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Alaee","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences , Tehran,","place":["Iran"]},{"name":"Students\u2019 Scientific Research Center, Tehran University of Medical Sciences , Tehran,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mousavi","sequence":"additional","affiliation":[{"name":"Department of Biology, Science and Research Branch, Islamic Azad University , Tehran,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghodratollah","family":"Panahi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences , Tehran,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Goodarzi","sequence":"additional","affiliation":[{"name":"School of Medicine, Arak University of Medical Sciences , Arak,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3860-5326","authenticated-orcid":false,"given":"Jamal","family":"Amri","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences , Tehran,","place":["Iran"]},{"name":"Students\u2019 Scientific Research Center, Tehran University of Medical Sciences , Tehran,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051319591487100_aqag028-B1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.21037\/tau-2025-103","article-title":"Global epidemiological trends in prostate cancer burden: a comprehensive analysis from Global Burden of Disease Study 2021","volume":"14","author":"Lin","year":"2025","journal-title":"Transl Androl Urol."},{"key":"2026051319591487100_aqag028-B2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1186\/s12885-025-14505-1","article-title":"The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer","volume":"25","author":"Ahamed","year":"2025","journal-title":"BMC cancer."},{"key":"2026051319591487100_aqag028-B3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12894-024-01634-1","article-title":"MicroRNA in prostate cancer: from biogenesis to applicative potential","volume":"24","author":"Luo","year":"2024","journal-title":"BMC Urol."},{"key":"2026051319591487100_aqag028-B4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-022-01525-9","article-title":"Liquid biopsy: exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer","volume":"21","author":"Preethi","year":"2022","journal-title":"Mol Cancer."},{"key":"2026051319591487100_aqag028-B5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40364-024-00697-4","article-title":"Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis","volume":"12","author":"Liu","year":"2024","journal-title":"Biomark Res."},{"key":"2026051319591487100_aqag028-B6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12894-017-0206-6","article-title":"miRNAs associated with prostate cancer risk and progression","volume":"17","author":"Luu","year":"2017","journal-title":"BMC Urol."},{"key":"2026051319591487100_aqag028-B7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3390\/biom15081156","article-title":"A brief review of microRNA profiling in human prostate cancer tissues and plasma","volume":"15","author":"Kallinikas","year":"2025","journal-title":"Biomolecules."},{"key":"2026051319591487100_aqag028-B8","doi-asserted-by":"crossref","first-page":"0","DOI":"10.35995\/tmj20220204","article-title":"Circulating microRNA-141 as a biomarker for prostate cancer: a systematic review and meta-analysis","volume":"2022","author":"Nitusca","year":"2022","journal-title":"Timisoara Med."},{"key":"2026051319591487100_aqag028-B9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/diagnostics10040188","article-title":"Profiling of circulating microRNAs in prostate cancer reveals diagnostic biomarker potential","volume":"10","author":"Freds\u00f8e","year":"2020","journal-title":"Diagnostics"},{"key":"2026051319591487100_aqag028-B10","doi-asserted-by":"crossref","first-page":"1352838","DOI":"10.3389\/fgene.2024.1352838","article-title":"Salivary miRNAs as auxiliary liquid biopsy biomarkers for diagnosis in patients with oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis","volume":"15","author":"Nguyen","year":"2024","journal-title":"Front Genet"},{"key":"2026051319591487100_aqag028-B11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13000-024-01575-1","article-title":"A new perspective on diagnostic strategies concerning the potential of saliva-based miRNA signatures in oral cancer","volume":"19","author":"Prasad","year":"2024","journal-title":"Diagn Pathol."},{"key":"2026051319591487100_aqag028-B12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/labmed\/lmaa013","article-title":"Serum and saliva levels of cancer antigen 15-3, carcinoembryonic antigen, estradiol, vaspin, and obestatin as biomarkers for the diagnosis of breast cancer in postmenopausal women","volume":"51","author":"Farahani","year":"2020","journal-title":"Lab Med."},{"key":"2026051319591487100_aqag028-B13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/ijms21030907","article-title":"Salivary microRNA for diagnosis of cancer and systemic diseases: a systematic review","volume":"21","author":"Setti","year":"2020","journal-title":"Int J Mol Sci."},{"key":"2026051319591487100_aqag028-B14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/biom12101366","article-title":"Prostate cancer-associated miRNAs in saliva: first steps to an easily accessible and reliable screening tool","volume":"12","author":"Luedemann","year":"2022","journal-title":"Biomolecules"},{"key":"2026051319591487100_aqag028-B15","doi-asserted-by":"crossref","first-page":"e9695","DOI":"10.1590\/1414-431x2020e9695","article-title":"miR-182 modulates cell proliferation and invasion in prostate cancer via targeting ST6GALNAC5","volume":"54","author":"Bai","year":"2021","journal-title":"Braz J Med Biol Res"},{"key":"2026051319591487100_aqag028-B16","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.7150\/jca.13176","article-title":"MiR-182 is associated with growth, migration and invasion in prostate cancer via suppression of FOXO1","volume":"6","author":"Wallis","year":"2015","journal-title":"J Cancer"},{"key":"2026051319591487100_aqag028-B17","doi-asserted-by":"crossref","first-page":"e55502","DOI":"10.1371\/journal.pone.0055502","article-title":"MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer","volume":"8","author":"Hirata","year":"2013","journal-title":"PloS one"},{"key":"2026051319591487100_aqag028-B18","first-page":"911","article-title":"Association of high miR-182 levels with low-risk prostate cancer","volume":"189","author":"Baumann","year":"2019","journal-title":"AJP."},{"key":"2026051319591487100_aqag028-B19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/CBM-210072","article-title":"MiR-96-5p induced NDRG1 deficiency promotes prostate cancer migration and invasion through regulating the NF-\u03ba B signaling pathway","volume":"35","author":"Lian","year":"2022","journal-title":"Cancer Biomark"},{"key":"2026051319591487100_aqag028-B20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-018-0450-6","article-title":"The miR-96 and RAR\u03b3 signaling axis governs androgen signaling and prostate cancer progression","volume":"38","author":"Long","year":"2019","journal-title":"Oncogene."},{"key":"2026051319591487100_aqag028-B21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s12032-014-0910-y","article-title":"MiR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells","volume":"31","author":"Yu","year":"2014","journal-title":"Medical oncology."},{"key":"2026051319591487100_aqag028-B22","doi-asserted-by":"crossref","first-page":"12023","DOI":"10.1007\/s13277-016-5058-2","article-title":"miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1","volume":"37","author":"Xu","year":"2016","journal-title":"Tumor Biology."},{"key":"2026051319591487100_aqag028-B23","doi-asserted-by":"crossref","first-page":"e99-e","DOI":"10.1038\/oncsis.2014.12","article-title":"MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo","volume":"3","author":"Hsu","year":"2014","journal-title":"Oncogenesis."},{"key":"2026051319591487100_aqag028-B24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3892\/ol.2015.4014","article-title":"Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker","volume":"11","author":"Al\u2011Kafaji","year":"2016","journal-title":"Oncol Lett"},{"key":"2026051319591487100_aqag028-B25","first-page":"2257","article-title":"Oncogenic miR-744 promotes prostate cancer growth through direct targeting of LKB1","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol Lett."},{"key":"2026051319591487100_aqag028-B26","doi-asserted-by":"crossref","first-page":"14693","DOI":"10.18632\/oncotarget.14711","article-title":"MicroRNA-744 promotes prostate cancer progression through aberrantly activating Wnt\/\u03b2-catenin signaling","volume":"8","author":"Guan","year":"2017","journal-title":"Oncotarget."},{"key":"2026051319591487100_aqag028-B27","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1002\/jcp.29548","article-title":"miR-210 is induced by hypoxia and regulates neural cell adhesion molecule in prostate cells","volume":"235","author":"Angel","year":"2020","journal-title":"J Cell Physiol."},{"key":"2026051319591487100_aqag028-B28","first-page":"1740","article-title":"Effects of microRNA-210 on the diagnosis and treatment of prostate cancer","volume":"18","author":"Qu","year":"2018","journal-title":"Mol Med Rep."},{"key":"2026051319591487100_aqag028-B29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.biopha.2017.10.040","article-title":"microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73","volume":"97","author":"Gao","year":"2018","journal-title":"Biomed Pharmacother."},{"key":"2026051319591487100_aqag028-B30","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1159\/000430313","article-title":"MiR-323 inhibits prostate cancer vascularization through adiponectin receptor","volume":"36","author":"Gao","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"2026051319591487100_aqag028-B31","article-title":"Long non-coding RNA TTN-AS1 promotes cell proliferation and inhibits cell apoptosis in prostatic cancer by sponging miR-193a-5p","volume":"23","author":"Luo","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026051319591487100_aqag028-B32","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/s41388-018-0602-8","article-title":"Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway","volume":"38","author":"Yang","year":"2019","journal-title":"Oncogene."},{"key":"2026051319591487100_aqag028-B33","doi-asserted-by":"crossref","first-page":"35978","DOI":"10.18632\/oncotarget.5427","article-title":"MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget."},{"key":"2026051319591487100_aqag028-B34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1158\/1940-6207.CAPR-10-0333","article-title":"Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo","volume":"4","author":"Hao","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"2026051319591487100_aqag028-B35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1476-4598-9-108","article-title":"MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1\u03b1\/HIF-1\u03b2","volume":"9","author":"Cao","year":"2010","journal-title":"Mol Cancer."},{"key":"2026051319591487100_aqag028-B36","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1186\/s12885-020-07472-2","article-title":"miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1","volume":"20","author":"Meng","year":"2020","journal-title":"BMC cancer."},{"key":"2026051319591487100_aqag028-B37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4161\/cc.10.7.15180","article-title":"MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines","volume":"10","author":"Viticchi\u00e8","year":"2011","journal-title":"Cell cycle"},{"key":"2026051319591487100_aqag028-B38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/labmed\/lmz053","article-title":"Serum and saliva concentrations of biochemical parameters in men with prostate cancer and benign prostate hyperplasia","volume":"51","author":"Farahani","year":"2020","journal-title":"Lab Med."},{"key":"2026051319591487100_aqag028-B39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000020354","article-title":"Free and total prostate\u2013specific antigen levels in saliva and the comparison with serum levels in men","volume":"38","author":"Turan","year":"2000","journal-title":"Eur Urol"},{"key":"2026051319591487100_aqag028-B40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12672-024-01376-4","article-title":"Recent progress in microRNA research for prostate cancer","volume":"15","author":"Yuan","year":"2024","journal-title":"Discov Oncol."},{"key":"2026051319591487100_aqag028-B41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.121.000896","article-title":"Circulating microRNAs as reliable tumor biomarkers: opportunities and challenges facing clinical application","volume":"384","author":"El-Daly","year":"2023","journal-title":"J Pharmacol Exp Ther."},{"key":"2026051319591487100_aqag028-B42","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3390\/ijms24031824","article-title":"MiR-182 is upregulated in prostate cancer and contributes to tumor progression by targeting MITF","volume":"24","author":"Stafford","year":"2023","journal-title":"Int J Mol Sci."},{"key":"2026051319591487100_aqag028-B43","doi-asserted-by":"crossref","first-page":"5873056","DOI":"10.1155\/2020\/5873056","article-title":"Circulating miRNAs as biomarkers for prostate cancer diagnosis in subjects with benign prostatic hyperplasia","volume":"2020","author":"Jin","year":"2020","journal-title":"J Immunol Res."},{"key":"2026051319591487100_aqag028-B44","doi-asserted-by":"crossref","first-page":"e68982","DOI":"10.1371\/journal.pone.0068982","article-title":"Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1)","volume":"8","author":"Liu","year":"2013","journal-title":"PloS one"},{"key":"2026051319591487100_aqag028-B45","doi-asserted-by":"crossref","first-page":"e72400","DOI":"10.1371\/journal.pone.0072400","article-title":"Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1","volume":"8","author":"Haflidad\u00f3ttir","year":"2013","journal-title":"PloS one"},{"key":"2026051319591487100_aqag028-B46","doi-asserted-by":"crossref","first-page":"153448","DOI":"10.1016\/j.prp.2021.153448","article-title":"Upregulation of miR-18a-5p promotes the proliferation of prostate cancer via inhibiting the expression of SLC40A1","volume":"224","author":"Liang","year":"2021","journal-title":"Pathol Res Pract."},{"key":"2026051319591487100_aqag028-B47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13046-017-0649-3","article-title":"Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel","volume":"36","author":"Yang","year":"2017","journal-title":"J Exp Clin Cancer Res."},{"key":"2026051319591487100_aqag028-B48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.reprotox.2022.04.003","article-title":"MiR-193a-5p serves as an inhibitor in ovarian cancer cells through RAB11A","volume":"110","author":"Wang","year":"2022","journal-title":"Reprod Toxicol"},{"key":"2026051319591487100_aqag028-B49","doi-asserted-by":"crossref","first-page":"e53823","DOI":"10.1371\/journal.pone.0053823","article-title":"Systematic transcriptome wide analysis of lncRNA-miRNA interactions","volume":"8","author":"Jalali","year":"2013","journal-title":"PloS one"},{"key":"2026051319591487100_aqag028-B50","doi-asserted-by":"crossref","first-page":"120215","DOI":"10.1016\/j.cca.2025.120215","article-title":"miR-210: A non-invasive biomarker for hypoxia-driven lung cancer diagnosis and therapy","author":"Goyal","year":"2025","journal-title":"Clin Chim Acta."},{"key":"2026051319591487100_aqag028-B51","doi-asserted-by":"crossref","first-page":"9778","DOI":"10.3390\/cimb45120611","article-title":"Impact of hypoxia-induced miR-210 on pancreatic cancer","volume":"45","author":"Lian","year":"2023","journal-title":"Curr Issues Mol Biol."},{"key":"2026051319591487100_aqag028-B52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-017-0688-6","article-title":"Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-\u03baB signaling pathway","volume":"16","author":"Ren","year":"2017","journal-title":"Mol Cancer."},{"key":"2026051319591487100_aqag028-B53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-015-0125-x","article-title":"MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer","volume":"34","author":"Xiang","year":"2015","journal-title":"J Exp Clin Cancer Res."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag028\/68281365\/aqag028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag028\/68281365\/aqag028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:59:22Z","timestamp":1778716762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag028\/8677692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag028","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"aqag028"}}